Use of prophylactic antifungals in the immunocompromised host

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 103, Issue SUPPL., 2007, Pages S6.e1-S6.e14

  Ship, Jonathan A ^a   Vissink, Arjan ^b   Challacombe, Stephen J ^c  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947221006     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2006.11.003     Document Type: Article

References (125)

1. Ship J.A., and Hu K. Radiotherapy-induced salivary dysfunction. Semin Oncol 31 6 Suppl 18 (2004) 29-36
2. Vissink A., Burlage F.R., Spijkervet F.K., Jansma J., and Coppes R.P. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 14 3 (2003) 213-225
3. Vissink A., Jansma J., Spijkervet F.K., Burlage F.R., and Coppes R.P. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14 3 (2003) 199-212
4. Worthington H.V., Eden O.B., and Clarkson J.E. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 4 (2004) CD003807
5. Pankhurst C. Candidiasis (oropharyngeal). Clin Evid 13 (2005) 1701-1716
6. Jensen S.B., Pedersen A.M., Reibel J., and Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11 4 (2003) 207-225
7. Amerongen A.V., and Veerman E.C. Saliva-the defender of the oral cavity. Oral Dis 8 1 (2002) 12-22
8. Farah C.S., Ashman R.B., and Challacombe S.J. Oral candidosis. Clin Dermatol 18 5 (2000) 553-562
9. Naglik J.R., Challacombe S.J., and Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67 3 (2003) 400-428
10. Goldman M., Cloud G.A., Wade K.D., Reboli A.C., Fichtenbaum C.J., Hafner R., et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 41 10 (2005) 1473-1480
11. Reichart P.A. Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma. Med Microbiol Immunol (Berl) 192 3 (2003) 165-169
12. Soysa N.S., Samaranayake L.P., and Ellepola A.N. Cytotoxic drugs, radiotherapy and oral candidiasis. Oral Oncol 40 10 (2004) 971-978
13. de Repentigny L., Lewandowski D., and Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 17 4 (2004) 729-759 table of contents
14. Belazi M., Velegraki A., Koussidou-Eremondi T., Andreadis D., Hini S., Arsenis G., et al. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 19 6 (2004) 347-351
15. Tanida T., Okamoto T., Okamoto A., Wang H., Hamada T., Ueta E., et al. Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. J Oral Pathol Med 32 10 (2003) 586-594
16. McCarthy G.M. Host factors associated with HIV-related oral candidiasis. A review. Oral Surg Oral Med Oral Pathol 73 2 (1992) 181-186
17. Stokman M.A., Spijkervet F.K., Burlage F.R., Dijkstra P.U., Manson W.L., de Vries E.G., et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer 88 7 (2003) 1012-1016
18. Sweet S.P. Selection and pathogenicity of Candida albicans in HIV infection. Oral Dis 3 Suppl 1 (1997) S88-S95
19. MacPhail L.A., Komaroff E., Alves M.E., Navazesh M., Phelan J.A., and Redford M. Differences in risk factors among clinical types of oral candidiasis in the Women's Interagency HIV Study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 1 (2002) 45-55
20. Samaranayake L.P., MacFarlane T.W., and Williamson M.I. Comparison of Sabouraud dextrose and Pagano-Levin agar media for detection and isolation of yeasts from oral samples. J Clin Microbiol 25 1 (1987) 162-164
21. Pfaller M.A., and Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 10 Suppl 1 (2004) 11-23
22. Reichart P.A., Samaranayake L.P., Samaranayake Y.H., Grote M., Pow E., and Cheung B. High oral prevalence of Candida krusei in leprosy patients in northern Thailand. J Clin Microbiol 40 12 (2002) 4479-4485
23. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., and Diekema D.J. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 42 7 (2004) 3142-3146
24. Fichtenbaum C.J., Koletar S., Yiannoutsos C., Holland F., Pottage J., Cohn S.E., et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 30 5 (2000) 749-756
25. Redding S.W., Kirkpatrick W.R., Dib O., Fothergill A.W., Rinaldi M.G., and Patterson T.F. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist 20 5 (2000) 178-181
26. Revankar S.G., Dib O.P., Kirkpatrick W.R., McAtee R.K., Fothergill A.W., Rinaldi M.G., et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 26 4 (1998) 960-963
27. Hersh E.V., and Moore P.A. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 135 3 (2004) 298-311
28. Park N.-H., and Kang M.K. Antifungal and antiviral agents. In: Yagiela J.A., Dowd F.J., and Neidel E.A. (Eds). Pharmacology and therapeutics for dentistry. 5th ed. (2004), Elsevier, St. Louis (MO) 660-676
29. Walmsley S., King S., McGeer A., Ye Y., and Richardson S. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin Infect Dis 32 11 (2001) 1554-1561
30. Bodey G.P., Samonis G., and Rolston K. Prophylaxis of candidiasis in cancer patients. Semin Oncol 17 3 Suppl 6 (1990) 24-28
31. Samonis G., Rolston K., Karl C., Miller P., and Bodey G.P. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 12 Suppl 3 (1990) S369-S373
32. Buchanan A.G., Riben P.D., Rayner E.N., Parker S.E., Ronald A.R., and Louie T.J. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. Clin Invest Med 8 2 (1985) 139-147
33. Cuttner J., Troy K.M., Funaro L., Brenden R., and Bottone E.J. Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Results of a double-blind study. Am J Med 81 5 (1986) 771-774
34. Cuttner J., Troy K., Funaro L., Brenden R., and Bottone E.J. Clotrimazole is effective in preventing oropharyngeal candidiasis in patients with leukemia undergoing chemotherapy. Proc ASCO 4 (1985) 258
35. Epstein J.B., Vickars L., Spinelli J., and Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 73 6 (1992) 682-689
36. Ferretti G.A., Ash R.C., Brown A.T., Largent B.M., Kaplan A., and Lillich T.T. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 114 4 (1987) 461-467
37. Ferretti G.A., Ash R.C., Brown A.T., Parr M.D., Romond E.H., and Lillich T.T. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 3 5 (1988) 483-493
38. Owens N.J., Nightingale C.H., Schweizer R.T., Schauer P.K., Dekker P.T., and Quintiliani R. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 144 2 (1984) 290-293
39. Vogler W.R., Malcom L.G., and Winton E.F. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest 5 4 (1987) 267-273
40. Chandrasekar P.H., and Gatny C.M. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. J Antimicrob Chemother 33 2 (1994) 309-318
41. Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar P.H., Fox B., Kaizer H., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 13 (1992) 845-851
42. Winston D.J., Chandrasekar P.H., Lazarus H.M., Goodman J.L., Silber J.L., Horowitz H., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 118 7 (1993) 495-503
43. Yeo E., Alvarado T., Fainstein V., and Bodey G.P. Prophylaxis of oropharyngeal candidiasis with clotrimazole. J Clin Oncol 3 12 (1985) 1668-1671
44. Brincker H. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 26 5 (1983) 242-247
45. Brincker H. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Med Scand 204 1-2 (1978) 123-128
46. Caselli D., Arico M., Michelone G., Cavanna C., Nespoli L., and Burgio G.R. Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study. Microbiologica 13 4 (1990) 347-351
47. Egger T., Gratwohl A., Tichelli A., Uhr M., Stebler Gysi C., Passweg J., et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer 3 2 (1995) 139-146
48. Hann I.M., Prentice H.G., Corringham R., Blacklock H.A., Keaney M., Shannon M., et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1 8276 (1982) 826-829
49. Huijgens P.C., Simoons-Smit A.M., van Loenen A.C., Prooy E., van Tinteren H., Ossenkoppele G.J., et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 52 5 (1999) 376-380
50. Menichetti F., Del Favero A., Martino P., Bucaneve G., Micozzi A., D'Antonio D., et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 120 11 (1994) 913-918
51. Menichetti F., Del Favero A., Martino P., Bucaneve G., Micozzi A., Girmenia C., et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 28 2 (1999) 250-255
52. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 13 4 (1994) 330-337
53. Groll A.H., Just-Nuebling G., Kurz M., Mueller C., Nowak-Goettl U., Schwabe D., et al. Fluconazole versus nystatin in the prevention of Candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 40 6 (1997) 855-862
54. Palmblad J., Lonnqvist B., Carlsson B., Grimfors G., Jarnmark M., Lerner R., et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias. J Intern Med 231 4 (1992) 363-370
55. Philpott-Howard J.N., Wade J.J., Mufti G.J., Brammer K.W., and Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 31 6 (1993) 973-984
56. Rozenberg-Arska M., Dekker A.W., Branger J., and Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 27 3 (1991) 369-376
57. Wahlin Y.B. Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 68 3 (1989) 279-287
58. Williams C., Whitehouse J.M., Lister T.A., and Wrigley P.F. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia. Med Pediatr Oncol 3 3 (1977) 275-280
59. Giorgis G.E., Galietti F., Massaglia G.M., Ardizzi A., Barberis S., Peraugine P., et al. Prevention of oropharyngeal mycosis using thymostimulin in patients with inoperable bronchogenic carcinoma. Minerva Pneumologica 30 (1991) 133-135
60. Orlandi E., Bernasconi C., Michelone G., Cavanna C., and Lombardi G. Mycotic infections in patients affected by acute myeloid leukemia. Clinical-microbiological evaluation of a protocol of anti-mycotic prophylaxis. Giornale di Malattie Infettive e Parassitarie 38 12 (1986) 1434-1437
61. Scrimgeour E., and Anderson J.D. Ketoconazole prophylaxis in patients with solid tumours receiving aggressive immunosuppressive therapy. An open randomized comparison between 200 mg/d and 400 mg/d doses. S Afr Med J 67 26 (1985) 1044-1045
62. Nucci M., Biasoli I., Akiti T., Silveira F., Solza C., Barreiros G., et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30 2 (2000) 300-305
63. Yamada T., Dan K., and Nomura T. Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern Med 32 9 (1993) 710-715
64. Patton L.L., Bonito A.J., and Shugars D.A. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 2 (2001) 170-179
65. Leen C.L., Dunbar E.M., Ellis M.E., and Mandal B.K. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 21 1 (1990) 55-60
66. Just-Nubling G., Gentschew G., Meissner K., Odewald J., Staszewski S., Helm E.B., et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 10 11 (1991) 917-921
67. Stevens D.A., Greene S.I., and Lang O.S. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 151 12 (1991) 2458-2464
68. Marriott D.J., Jones P.D., Hoy J.F., Speed B.R., and Harkness J.L. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust 158 5 (1993) 312-316
69. Schuman P., Capps L., Peng G., Vazquez J., el-Sadr W., Goldman A.I., et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 126 9 (1997) 689-696
70. Pagani J.L., Chave J.P., Casjka C., Glauser M.P., and Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 50 2 (2002) 231-240
71. Smith D., Midgley J., and Gazzard B. A randomised, double-blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection. Int J Clin Pract 53 5 (1999) 349-352
72. Smith D.E., Bell J., Johnson M., Youle M., Gazzard B., Tchamouroff S., et al. A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Med 2 2 (2001) 78-83
73. Chariyalertsak S., Supparatpinyo K., Sirisanthana T., and Nelson K.E. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 34 2 (2002) 277-284
74. MacPhail L.A., Hilton J.F., Dodd C.L., and Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 12 5 (1996) 470-476
75. Powderly W.G., Finkelstein D., Feinberg J., Frame P., He W., van der Horst C., et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 332 11 (1995) 700-705
76. Revankar S.G., Kirkpatrick W.R., McAtee R.K., Dib O.P., Fothergill A.W., Redding S.W., et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med 105 1 (1998) 7-11
77. Havlir D.V., Dube M.P., McCutchan J.A., Forthal D.N., Kemper C.A., Dunne M.W., et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 27 6 (1998) 1369-1375
78. Laine L., and Rabeneck L. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment Pharmacol Ther 9 5 (1995) 553-556
79. Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 4 (2002) 225-234
80. Spijkervet F.K., Van Saene H.K., Van Saene J.J., Panders A.K., Vermey A., Mehta D.M., et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 46 3 (1991) 167-173
81. Spijkervet F.K., van Saene H.K., Panders A.K., Vermey A., van Saene J.J., Mehta D.M., et al. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol 67 2 (1989) 154-161
82. Epstein J.B., Truelove E.L., Hanson-Huggins K., Mancl L.A., Chen A., Press O.W., et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer 12 7 (2004) 517-525
83. Gombert M.E., duBouchet L., Aulicino T.M., and Butt K.M. A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxis of oropharyngeal candidiasis. JAMA 258 18 (1987) 2553-2555
84. Lumbreras C., Cuervas-Mons V., Jara P., del Palacio A., Turrion V.S., Barrios C., et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 174 3 (1996) 583-588
85. Ruskin J.D., Wood R.P., Bailey M.R., Whitmore C.K., and Shaw B.W. Comparative trial of oral clotrimazole and nystatin for oropharyngeal candidiasis prophylaxis in orthotopic liver transplant patients. Oral Surg Oral Med Oral Pathol 74 5 (1992) 567-571
86. Millns B., and Martin M.V. Nystatin pastilles and suspension in the treatment of oral candidosis. Br Dent J 181 6 (1996) 209-211
87. Encarnacion M., and Chin I. Salivary nystatin concentrations after administration of an osmotic controlled release tablet and a pastille. Eur J Clin Pharmacol 46 6 (1994) 533-535
88. Barkvoll P., and Attramadal A. Effect of nystatin and chlorhexidine digluconate on Candida albicans. Oral Surg Oral Med Oral Pathol 67 3 (1989) 279-281
89. Bader M.S., Lai S.M., Kumar V., and Hinthorn D. Candidemia in patients with diabetes mellitus: epidemiology and predictors of mortality. Scand J Infect Dis 36 11-12 (2004) 860-864
90. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 Suppl 5 (1997) S1-S85
91. Guggenheimer J., Moore P.A., Rossie K., Myers D., Mongelluzzo M.B., Block H.M., et al. Insulin-dependent diabetes mellitus and oral soft tissue pathologies: II. Prevalence and characteristics of Candida and Candidal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89 5 (2000) 570-576
92. Fanello S., Bouchara J.P., Sauteron M., Delbos V., Parot E., Marot-Leblond A., et al. Predictive value of oral colonization by Candida yeasts for the onset of a nosocomial infection in elderly hospitalized patients. J Med Microbiol 55 Pt 2 (2006) 223-228
93. Grimoud A.M., Lodter J.P., Marty N., Andrieu S., Bocquet H., Linas M.D., et al. Improved oral hygiene and Candida species colonization level in geriatric patients. Oral Dis 11 3 (2005) 163-169
94. Fenlon M.R., Sherriff M., and Walter J.D. Factors associated with the presence of denture related stomatitis in complete denture wearers: a preliminary investigation. Eur J Prosthodont Restor Dent 6 4 (1998) 145-147
95. Sakki T.K., Knuuttila M.L., Laara E., and Anttila S.S. The association of yeasts and denture stomatitis with behavioral and biologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84 6 (1997) 624-629
96. Tsai H.F., Krol A.A., Sarti K.E., and Bennett J.E. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother 50 4 (2006) 1384-1392
97. Burn A.K., Fothergill A.W., Kirkpatrick W.R., Coco B.J., Patterson T.F., McCarthy D.I., et al. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients. J Clin Microbiol 42 12 (2004) 5846-5848
98. Playford E.G., Webster A.C., Sorrell T.C., and Craig J.C. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 1 (2006) CD004920
99. Scharfstein J.A., Paltiel A.D., and Freedberg K.A. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 17 4 (1997) 373-381
100. Baily G. Weekly fluconazole for preventing mucosal candidiasis in HIV infection. Ann Intern Med 127 12 (1997) 1131
101. Baily G.G., Perry F.M., Denning D.W., and Mandal B.K. Fluconazole-resistant candidosis in an HIV cohort. AIDS 8 6 (1994) 787-792
102. Redding S.W., Dahiya M.C., Kirkpatrick W.R., Coco B.J., Patterson T.F., Fothergill A.W., et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97 1 (2004) 47-52
103. Rex J.H., Walsh T.J., Sobel J.D., Filler S.G., Pappas P.G., Dismukes W.E., et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30 4 (2000) 662-678
104. Marr K.A., Seidel K., White T.C., and Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 1 (2000) 309-316
105. Safdar A., van Rhee F., Henslee-Downey J.P., Singhal S., and Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 28 9 (2001) 873-878
106. Kuc I.M., Samaranayake L.P., and van Heyst E.N. Oral health and microflora in an institutionalised elderly population in Canada. Int Dent J 49 1 (1999) 33-40
107. Ellepola A.N., and Samaranayake L.P. Adhesion of oral Candida albicans isolates to denture acrylic following limited exposure to antifungal agents. Arch Oral Biol 43 12 (1998) 999-1007
108. Johnson G.H., Taylor T.D., and Heid D.W. Clinical evaluation of a nystatin pastille for treatment of denture-related oral candidiasis. J Prosthet Dent 61 6 (1989) 699-703
109. Webb B.C., Thomas C.J., and Whittle T. A 2-year study of Candida-associated denture stomatitis treatment in aged care subjects. Gerodontology 22 3 (2005) 168-176
110. Samaranayake Y.H., Ye J., Yau J.Y., Cheung B.P., and Samaranayake L.P. In vitro method to study antifungal perfusion in Candida biofilms. J Clin Microbiol 43 2 (2005) 818-825
111. Samaranayake L.P., and MacFarlane T.W. Oral candidosis (1990), Wright, London
112. Colombo A.L., Perfect J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 8 (2003) 470-474
113. Arendrup M., Horn T., and Frimodt-Moller N. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30 5 (2002) 286-291
114. Redding S.W., Zellars R.C., Kirkpatrick W.R., McAtee R.K., Caceres M.A., Fothergill A.W., et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 37 12 (1999) 3896-3900
115. Samaranayake L.P., MacFarlane T.W., Lamey P.J., and Ferguson M.M. A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. J Oral Pathol 15 7 (1986) 386-388
116. Spijkervet F.K., Van Saene H.K., Panders A.K., and Vermey A. Colonisation index of the oral cavity: a novel technique for monitoring colonisation defense. Microbiol Ecol Health Dis 2 (1989) 145-151
117. Epstein J.B., Pearsall N.N., and Truelove E.L. Quantitative relationships between Candida albicans in saliva and the clinical status of human subjects. J Clin Microbiol 12 3 (1980) 475-476
118. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 9495 (2005) 1435-1442
119. Kauffman C.A. Fungal infections. Proc Am Thorac Soc 3 1 (2006) 35-40
120. Elahi S., Pang G., Ashman R., and Clancy R. Enhanced clearance of Candida albicans from the oral cavities of mice following oral administration of Lactobacillus acidophilus. Clin Exp Immunol 141 1 (2005) 29-36
121. Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 56 Suppl 1 (2005) i49-i54
122. Deck D.H., and Guglielmo B.J. Pharmacological advances in the treatment of invasive candidiasis. Expert Rev Anti Infect Ther 4 1 (2006) 137-149
123. Helmerhorst E.J., Troxler R.F., and Oppenheim F.G. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Natl Acad Sci U S A 98 25 (2001) 14637-14642
124. Oppenheim F.G., Xu T., McMillian F.M., Levitz S.M., Diamond R.D., Offner G.D., et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 263 16 (1988) 7472-7477
125. van 't Hof W., Veerman E.C., Helmerhorst E.J., and Amerongen A.V. Antimicrobial peptides: properties and applicability. Biol Chem 382 4 (2001) 597-619